Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

[1]  A. Paller,et al.  Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials , 2021, The Lancet.

[2]  A. Linneberg,et al.  No association between atopic dermatitis and acne vulgaris in the general population , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  J. Silverberg,et al.  Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis , 2020, JAMA dermatology.

[4]  B. Elewski,et al.  Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial* , 2020, The British journal of dermatology.

[5]  K. Peris,et al.  Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* , 2020, The British journal of dermatology.

[6]  A. Gottlieb,et al.  Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial , 2020, The Lancet.

[7]  V. Strand,et al.  Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial , 2020, Arthritis & rheumatology.

[8]  J. Silverberg,et al.  Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis , 2020, JAMA dermatology.

[9]  S. Feldman,et al.  The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. , 2020, Journal of the American Academy of Dermatology.

[10]  D. Hijnen.  Shifting paradigms in the immunology of atopic dermatitis. , 2020, The Journal of allergy and clinical immunology.

[11]  J. Silverberg,et al.  Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials , 2020, The British journal of dermatology.

[12]  A. Mócsai,et al.  Neutrophils as emerging therapeutic targets , 2020, Nature Reviews Drug Discovery.

[13]  N. Lévêque,et al.  Eczema Herpeticum: Clinical and Pathophysiological Aspects , 2019, Clinical Reviews in Allergy & Immunology.

[14]  J. Silverberg,et al.  Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial. , 2019, Journal of Allergy and Clinical Immunology.

[15]  Linghong Guo,et al.  Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  P. Emery,et al.  Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study , 2019, The Lancet.

[17]  Kara Queeney,et al.  FRI0131 ELUCIDATING THE MECHANISM UNDERLYING CREATINE PHOSPHOKINASE UPREGULATION WITH UPADACITINIB , 2019, Poster Presentations.

[18]  E. Guttman‐Yassky,et al.  JAK Inhibitors for Atopic Dermatitis: An Update , 2018, American Journal of Clinical Dermatology.

[19]  L. Olson,et al.  In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) , 2018, BMC Rheumatology.

[20]  T. Bieber,et al.  Atopic dermatitis , 2018, Nature Reviews Disease Primers.

[21]  G. Yancopoulos,et al.  Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.

[22]  J. Silverberg,et al.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.

[23]  C. Bruijnzeel-Koomen,et al.  Drug survival for azathioprine and enteric‐coated mycophenolate sodium in a long‐term daily practice cohort of adult patients with atopic dermatitis , 2016, The British journal of dermatology.

[24]  C. Bruijnzeel-Koomen,et al.  Drug survival for ciclosporin A in a long‐term daily practice cohort of adult patients with atopic dermatitis , 2015, The British journal of dermatology.

[25]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. , 2014, Journal of the American Academy of Dermatology.

[26]  R. Hay,et al.  The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. , 2014, The Journal of investigative dermatology.

[27]  Andrew D Westwell,et al.  The role of fluorine in medicinal chemistry , 2007, Journal of enzyme inhibition and medicinal chemistry.

[28]  G. Plewig,et al.  Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. , 2003, Journal of the American Academy of Dermatology.

[29]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.

[30]  R. Schwartz,et al.  Adverse effects of topical glucocorticosteroids. , 2006, Journal of the American Academy of Dermatology.